Nuformix PLC Convertible Loan Amendment (0266Z)
August 28 2018 - 7:55AM
UK Regulatory
TIDMNFX
RNS Number : 0266Z
Nuformix PLC
28 August 2018
28 August 2018
Nuformix plc
("Nuformix" or the "Company")
Renewal of Loan Notes
Nuformix, the pharmaceutical development company using cocrystal
technology to unlock the therapeutic potential of approved small
molecule drugs, announces that it has agreed to amend the terms of
the Convertible Loan Agreement ("Loan") dated 18th April 2017,
extending the loan until 18th April 2019.
The conversion price of any outstanding loans and any accrued
interest into shares and warrants has been set at 2.75p per share
and such warrants are exercisable at any time for 60 months from
the date on which the warrants were granted. The 2.75p conversion
price represents a 8% premium to the closing price on 23 August
2018, the day prior to the amended agreement being signed.
Market Abuse Regulation (MAR) Disclosure. Certain information
contained in this announcement would have been deemed inside
information for the purposes of Article 7 of Regulation (EU) No
596/2014 until the publication of this announcement via a
Regulatory Information Service and accordingly, this inside
information is now considered to be in the public domain.
Enquiries:
Nuformix plc
Dr Dan Gooding, Chief Executive
Officer +44 (0)1223 423667
Gable Communications Ltd
John Bick / Justine James +44 (0)20 7193 7463
About Nuformix plc www.nuformix.com
Nuformix is a pharmaceutical development company using cocrystal
technology to unlock the therapeutic potential of approved small
molecule drugs. Nuformix's risk-mitigated development strategy has
resulted in a pipeline of discoveries through which it has
developed and patented novel cocrystal forms of approved small
molecules.
Nuformix has created an IP portfolio containing a range of
granted patents covering cocrystal forms of five small molecule
drugs. Nuformix is targeting high-value unmet needs with its lead
programmes in oncology supportive care: NXP001 and fibrosis:
NXP002.
Nuformix was established in Cambridge in 2009 and has invested
into pharmaceutical cocrystal R&D, establishing world-class
capability and know-how in cocrystal discovery and development,
yielding multiple product opportunities. Nuformix plc shares are
traded on the London Stock Exchange's Official List under the
ticker: NFX.L.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCPGUWARUPRGGR
(END) Dow Jones Newswires
August 28, 2018 07:55 ET (11:55 GMT)
Nuformix (LSE:NFX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nuformix (LSE:NFX)
Historical Stock Chart
From Sep 2023 to Sep 2024